The rise of Sildenafil initially fueled a boom for the drug industry, nevertheless recent shifts present a complicated outlook for shareholders. Off-patent alternatives are eroding profits, and ongoing legal battles https://craigijvs173383.arwebo.com/63703585/the-blue-pill-and-pharma-a-precarious-investment